You are here: Industry Insights > NICE

News List

NICE publishes new draft guideline covering rehabilitation after traumatic injury pharmatimes
July 28, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has published a new draft guideline, focused on rehabilitation after traumatic injury.
NICE, PHE publish new antimicrobial prescribing guideline on C. difficile infection pharmatimes
July 26, 2021
The UK’s National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) have published a new jointly developed guideline on antimicrobial prescribing for Clostridioides difficile (C. difficile) infection.
NICE recommends Incyte’s Pemazyre for rare bile duct cancer pharmatimes
July 23, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Incyte Biosciences UK’s Pemazyre for the treatment of the rare bile duct cancer cholangiocarcinoma (CCA).
NHS England unveils new Innovative Medicine Fund pharmatimes
July 22, 2021
NHS England has unveiled its new Innovative Medicines Fund (IMF), to ensure patients have early access to ‘potentially life-saving’ new treatments.
UK to launch research studies to develop long Covid therapies pharmaceutical-technology
July 20, 2021
The UK Government has announced plans to commence a research programme comprising of 15 new studies to develop new therapies for long Covid and enhance diagnosis.
Ledaga recommended by NICE for rare type of lymphoma pharmatimes
July 19, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Recordati Rare Diseases and Helsinn Healthcare’s Ledaga for a type of lymphoma that affects the skin.
NICE’s decision not to approve Zytiga ‘frustrating’, says ICR pharmatimes
July 16, 2021
The National Institute of Health and Care Excellence (NICE) has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the drug in 2020.
NICE to develop guideline for rare blood clots associated with COVID-19 vaccination pharmatimes
July 15, 2021
The National Institute for Health and Care Excellence (NICE) will develop a guideline on the management and treatment of rare blood clots and low platelet counts associated with COVID-19 vaccination.
NICE ‘no’ for Orchard Therapeutics’ gene therapy Libmeldy pharmatimes
July 13, 2021
The National Institute for Health and Care Excellence (NICE) has announced that it does not recommend Orchard Therapeutics’ gene therapy Libmeldy for the treatment of metachromatic leukodystrophy (MLD) in children.
Expanded access for Zolgensma following final NICE guidance pharmatimes
July 12, 2021
The National Institute for Health and Care Excellence (NICE) has published its final guidance on Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page